Abstract
Although the vast majority of confirmed cases of COVID-19 are in low- and middle-income countries, there are relatively few published studies on the epidemiology of SARS-CoV-2 in these countries. The few there are focus on disease prevalence in urban areas. We conducted state-wide surveillance for COVID-19, in both rural and urban areas of Karnataka between June 15-August 29, 2020. We tested for both viral RNA and antibodies targeting the receptor binding domain (RBD). Adjusted seroprevalence across Karnataka was 46.7% (95% CI: 43.3-50.0), including 44.1% (95% CI: 40.0-48.2) in rural and 53.8% (95% CI: 48.4-59.2) in urban areas. The proportion of those testing positive on RT-PCR, ranged from 1.5 to 7.7% in rural areas and 4.0 to 10.5% in urban areas, suggesting a rapidly growing epidemic. The relatively high prevalence in rural areas is consistent with the higher level of mobility measured in rural areas, perhaps because of agricultural activity. Overall seroprevalence in the state implies that by August at least 31.5 million residents had been infected by August, nearly an order of magnitude larger than confirmed cases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Action Covid-19 Team (ACT) grant awarded to IDFC Foundation (Mumbai, India).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Government of India (the Prime Minister's Principal Scientific Advisor's Office) and the Government of Karnataka. The study protocols were also approved by IRB / IEC committees at three institutions: Karesa (ECR/308/Indt/KA/2018, Approval date June 3, 2020), for Anu Acharya (Mapmygenome); Duke University (Protocol 2020-0553); and University of Chicago (IRB20-1484). Because Mohanan (Duke) and Malani (University of Chicago) only received de-identified data, the research was determined to be exempt from IRB review at their institutions.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
manoj.mohanan{at}duke.edu
amalani{at}uchicago.edu
kkrishnan{at}cmie.com
anu{at}mapmygenome.in
Results section updated to include seropositivity results by age and homogeneous region.
1 Chaudhuri S, Thiruvengadam R, Chattopadhyay S, et al. Comparative evaluation of SARS-CoV-2 IgG assays in India. Journal of Clinical Virology. 2020;131:104609.
2 See https://www.fda.gov/media/137742/download and https://www.biomerieux-usa.com/sites/subsidiary_us/files/eua-biom-gene-letter.pdf.
3 Details on methods at https://consumerpyramidsdx.cmie.com/kommon/bin/sr.php?kall=wkb.
Data Availability
We will make test results available on a de-identified basis 9 months after publication.
